Novacyt: on these numbers, the cheapest stock on the market
AIM’s top performer from 2020 announces fabulous numbers, but that was last year, what of the future?
Novacyt (EURONEXT GROWTH: ALNOV; LON: NCYT ), the clinical diagnostics specialist and superstar performer from 2020, updated on trading for the year ending 31 December 2020. Here are the astonishing highlights from an incredible year:
EBITDA profitability above €210m (£187m), representing an EBITDA margin of more than 67%, after adding 124 people to the payroll.
Cash at 31 December 2020 was…
Sign up and read the full article
Register to continue reading our content.
Already a member? Login
Previous article Next article
DON'T MISS OUT!
Get top investment ideas to help safeguard and grow your wealth.
Invaluable insight from the exciting world of smaller companies.REGISTER FREE
More on Novacyt SA
AIM’s top performer in 2020 has fallen back to earth after a disappointing trading update. Are…
Bonkers Bargains, new Covid tests, kettle controls, video game developers and franchised lettings – such are…